author-photo

Zhangzhou Huang

Fujian Medical University

8

Papers

42

Citations

Citation Trend

Filter By

Papers (8) Sort By

Journal Conference Others

A phase II study of sintilimab plus anlotinib for Chinese patients (pts) with persistent, recurrent or metastatic cervical cancer (CC)

2021 Gynecologic Oncology
Show All
- Source
- Cite
- Save
Citations (0)
Anlotinib plus sintilimab in patients with recurrent advanced cervical cancer: A prospective, multicenter, single-arm, phase II clinical trial.

2021 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (0)
The deep learning model combining CT image and clinicopathological information for predicting ALK fusion status and response to ALK-TKI therapy in non-small cell lung cancer patients.

2020 European Journal of Nuclear Medicine and Molecular Imaging
Show All
- Source
- Cite
- Save
Citations (3)
Prognostic Value of the Lung Immune Prognostic Index May Differ in Patients Treated With Immune Checkpoint Inhibitor Monotherapy or Combined With Chemotherapy for Non-small Cell Lung Cancer

2020 Frontiers in Oncology
Show All
- Source
- Cite
- Save
Citations (3)
Ginsenoside compound K inhibits growth of lung cancer cells via HIF-1α-mediated glucose metabolism

2019 Cellular and Molecular Biology
Show All
- Source
- Cite
- Save
Citations (9)
Prognostic factor analysis of elderly patients with small-cell lung cancer

2019 Chinese Journal of Geriatrics
Show All
- Source
- Cite
- Save
Citations (0)
The tumor mutational Burden of Chinese advanced cancer patients estimated by a 381-cancer-gene Panel

2018 Journal of Cancer
Show All
- Source
- Cite
- Save
Citations (14)
TP53 mutations predict for poor survival in ALK rearrangement lung adenocarcinoma patients treated with crizotinib

2018 Journal of Thoracic Disease
Show All
- Source
- Cite
- Save
Citations (13)